Arrowhead Pharmaceuticals (NASDAQ: ARWR) recently received a number of ratings updates from brokerages and research firms: 12/8/2020 – Arrowhead Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating. 11/24/2020 – Arrowhead Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald from $58.00 to $80.00. They now have […]
